A comparison of the effect of omega-3 alone versus omega-3/Vitamin D3 co-supplementation therapy on 25-hydroxyvitamin D levels in adults with vitamin D deficiency.

Background: Omega-3 fatty acid (n-3FA) supplementation may improve total hydroxyvitamin D (25OHD) levels in people with normal or low vitamin D levels. However, there was no agreement on the potential therapeutic benefit of n-3FA on vitamin D toxicity. Objective: The current randomized controlled cl...

Descripción completa

Detalles Bibliográficos
Publicado en:Pharmacy Practice (1886-3655) Vol. 23; no. 1; pp. 1 - 10
Autores principales: Mohammad, Beisan A., Oriquat, Ghaleb Ali, Khader, Heba A., Farah, Husni Shukri, Alsayed, Ahmad R., Alhmoud, Jehad F., Al-Najjar, Mohammad A. A., Hasoun, Luai, Abdelhalim, Shaimaa M., Awwad, Shady, Abu-Samak, Mahmoud S.
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas S.L. Jan-Mar2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=185112640&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 185112640
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1885642X
        3EAU
      jtl: Pharmacy Practice (1886-3655)
      issn: 1885642X
      maglogo: N
    pubinfo:
      dt: Jan-Mar2025
      vid: 23
      iid: 1
      pid: 36266
      pub: Centro de Investigaciones y Publicaciones Farmaceuticas S.L.
    artinfo:
      ui:
        185112640
        185112640
        185112640
        10.18549/PharmPract.2025.1.3050
        185112640
      ppf: 1
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: A comparison of the effect of omega-3 alone versus omega-3/Vitamin D3 co-supplementation therapy on 25-hydroxyvitamin D levels in adults with vitamin D deficiency.
      aug:
        au:
          Mohammad, Beisan A.
          Oriquat, Ghaleb Ali
          Khader, Heba A.
          Farah, Husni Shukri
          Alsayed, Ahmad R.
          Alhmoud, Jehad F.
          Al-Najjar, Mohammad A. A.
          Hasoun, Luai
          Abdelhalim, Shaimaa M.
          Awwad, Shady
          Abu-Samak, Mahmoud S.
        affil: Harmaceutical Sciences Department- PharmD Program, Fakeeh College for Medical Sciences, Jeddah 21461, Saudi Arabia
      sug:
        subj:
          Fatty Acids, omega-3 Adverse Effects
          Fatty Acids, omega-3 Therapeutic Use
          Cholecalciferol Therapeutic Use
          Dietary Supplementation
          Drug Therapy, Combination
          Vitamin D Blood
          Biological Markers Blood
          Vitamin D Deficiency Drug Therapy
          Drug Efficacy
          Human
          Jordan
          Funding Source
          Randomized Controlled Trials
          Random Assignment
          Male
          Female
          Adult
          Middle Age
          Fatty Acids, omega-3 Administration and Dosage
          Cholecalciferol Administration and Dosage
          After Care
          Parathyroid Hormones Blood
          Calcium Blood
          Leptin Blood
          Descriptive Statistics
          Cardiovascular Risk Factors
          COVID-19 Risk Factors
          Risk Assessment
          Hypervitaminosis Complications
          Overdose Complications
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Background: Omega-3 fatty acid (n-3FA) supplementation may improve total hydroxyvitamin D (25OHD) levels in people with normal or low vitamin D levels. However, there was no agreement on the potential therapeutic benefit of n-3FA on vitamin D toxicity. Objective: The current randomized controlled clinical study (RCT) sought to determine if daily omega-3 fatty acid (n-3FA) supple-mentation affected 25-hydroxyvitamin D (25OHD) levels. Methods: One hundred and twenty Jordanians aged 22 to 55 were randomly allocated into three groups supplemented with the dose of 50,000 IU VD3 taken weekly (D3) alone, 300 mg n-3FA taken daily (n-3FA) alone, or their com-bination (50,000 IU VD3 taken weekly + 300 mg n-3FA taken daily (D+). In addition, fasting baseline and follow-up (ten weeks; eight weeks supplementation plus two weeks washout) of serum 25 hydroxyvitamin D (25OHD), parathyroid hormone (PTH), calcium, and leptin were assayed. Results: The n-3FA supplementation significantly decreased mean serum 25OHD levels (11.97±4.6 vs 16.5±4.8, P<0.001) compared with their peers in the D3 group who showed a significant increase in 25OHD levels (41.15±11.7 vs 19.34±6.8, P<0.001). The follow-up PTH mean levels were pro-portionally accompanied by significant alterations of 25OHD levels in the two study groups. Conclusions: This novel RCT provides that eight weeks of n-3FA therapy significantly reduced 25OHD levels, which adverse effects may accompany vitamin D status and its health-related consequences, such as bone homeostasis, cardiovascular disease, and COVID-19 conditions.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N